AZN AstraZeneca PLC

LSE · GB · Healthcare · Drug Manufacturers - General · astrazeneca.com

11794.00GBP-0.64%Mkt Cap: 236.12B $P/E: 23.69Today

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza,…

Industry Peers

Drug Manufacturers - General

Screen all

LLY

Eli Lilly and Company Common Stock

$1.02TUSDP/E 38.4

JNJ

Johnson & Johnson Common Stock

$617.01BUSDP/E 29.7

ABBV

AbbVie Inc. Common Stock

$464.43BUSDP/E 74.2

MRK

Merck & Company, Inc. Common Stock (new)

Novartis AG Common Stock

Amgen Inc. - Common Stock

$217.90BUSDP/E 25.0

GILD

Gilead Sciences, Inc. - Common Stock

$179.47BUSD

NVO

Novo Nordisk A/S Common Stock

$164.79BUSDP/E 9.4

PFE

Pfizer, Inc. Common Stock

$158.45BUSDP/E 36.6

BMY

Bristol-Myers Squibb Company Common Stock

$124.91BUSDP/E 13.5

SNY

Sanofi - American Depositary Shares

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Bayer Aktiengesellschaft

$47.99BUSD

BIIB

Biogen Inc. - Common Stock

$32.49BUSDP/E 39.1

MRV

Marvell Technology, Inc.

Key Statistics

Company

Market Cap236.12B USD

Enterprise Value271.35B USD

Revenue (TTM)78.71B USD

Gross Profit61.70B USD

Net Income (TTM)13.11B USD

Revenue/Share39.59 GBP

Last Price11794.00 GBP

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees96.1K

CountryGB

SectorHealthcare

IndustryDrug Manufacturers - General

ISINGB0009895292

Valuation

P/E (Trailing)23.69

P/E (Forward)13.73

PEG1.10

EV/EBITDA10.63

EV/Revenue3.45

P/S3.00

P/B4.89

EPS (TTM)4.99

EPS (Forward)8.65

52W Range

0.000075% of range15830.00

52W High15830.00 GBP

52W Low0.0000 GBP

Profitability

Gross Margin81.90%

Oper. Margin23.46%

EBITDA Margin32.44%

Profit Margin17.41%

ROE21.01%

ROA8.96%

Growth

Revenue Growth6.40%

Earnings Growth2.50%

Cash Flow & Leverage

Operating CF18.69B USD

CapEx (TTM)7.57B USD

FCF Margin7.99%

FCF Yield2.66%

Net Debt35.12B USD

Net Debt/EBITDA1.38

Balance Sheet

Debt/Equity0.60

Current Ratio0.89

Quick Ratio0.66

Book Value/Sh24.28 GBP

Cash/Share3.20 GBP

Dividends

Fwd Div Rate2.39 GBP

Trail. Div Rate3.23 GBP

Div. Yield2.01%

5Y Avg Yield2.04%

Payout Ratio46.95%

Ex-Div DateAug 6, 2026

Pay Date—

Analyst Consensus

Rating1.7 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)15897.44 GBP

Upside (mean)+34.8%

Target Range11912.60 GBP – 20226.24 GBP

11912.60+34.8% to mean20226.24

# Analysts23

Ownership

Shares Out.1.55B

Float1.54B

Insiders0.05%

Institutions65.02%

Technical

SMA 5012136.64 (-2.8%)

SMA 20013568.69 (-13.1%)

Beta0.20

S&P 52W Chg14.58%

Avg Vol (30d)2.95M

Avg Vol (10d)2.78M

Technical Indicators

RSI (14)39.7

MACD-16.6901

MACD Signal10.8237

MACD Hist.-27.5139

BB Upper12809.97 GBP

BB Middle12230.10 GBP

BB Lower11650.23 GBP

BB Width9.48%

ATR (14)312.28 GBP

Vol Ratio (20d)0.52x